Lyrica vs Gabapentin for Nerve Pain: How They Compare and What Else Helps

Nerve pain affects roughly 10% of U.S. adults, and two of the most commonly prescribed medications for it are Lyrica (pregabalin) and gabapentin. Both belong to the same drug class, but they differ in FDA approvals, dosing, cost, and scheduling. Choosing between them often comes down to a conversation between you and your prescribing clinician.

This article breaks down how Lyrica and gabapentin compare on efficacy, side effects, and cost. It then explores what non-drug options have evidence for nerve pain relief when medication alone does not fully resolve symptoms.

Key Takeaways

• Lyrica and gabapentin are both gabapentinoids that reduce nerve pain by targeting calcium channels in the nervous system.
• Pregabalin has a slightly faster onset in clinical comparisons, but the overall efficacy difference between the two is modest.
• Gabapentin is typically less expensive and is not a federally controlled substance, unlike pregabalin (Schedule V).
• Behavioral approaches like CBT have evidence for reducing pain interference in adults with diabetic neuropathy.
• Non-drug options work alongside medication, not necessarily instead of it, and a coordinated plan with a clinician tends to produce better results.

What Are Lyrica and Gabapentin?

Lyrica (pregabalin) and gabapentin (often sold as Neurontin) are both gabapentinoids, a class of medications originally developed for epilepsy that became widely used for neuropathic pain. They are not opioids, and they work through a different mechanism than most pain medications.

Both drugs bind to the alpha-2-delta-1 subunit of voltage-gated calcium channels in the nervous system. In neuropathic pain conditions, these subunits become overexpressed in sensory neurons, contributing to heightened pain signaling. By binding this subunit, gabapentinoids reduce the release of excitatory neurotransmitters at nerve synapses, which helps dampen the amplified pain signals that characterize nerve pain.

Despite sharing a mechanism, the two drugs differ in how they are absorbed. Pregabalin has more predictable absorption (linear pharmacokinetics), meaning blood levels increase proportionally with dose. Gabapentin's absorption is dose-dependent and less predictable at higher doses, which is why it typically requires more frequent dosing throughout the day.

FDA-Approved Uses: Where Each Medication Fits

The two drugs have overlapping but distinct FDA approvals:

Pregabalin has a broader approval profile, including diabetic nerve pain, fibromyalgia, and neuropathic pain from spinal cord injury. Gabapentin is FDA-approved for postherpetic neuralgia and epilepsy in adults, though clinicians frequently prescribe it off-label for other neuropathic pain conditions.

A separate formulation, gabapentin enacarbil (Horizant), is approved for restless legs syndrome and postherpetic neuralgia but is a different product with different dosing.

How They Compare on Pain Relief

Head-to-head data between pregabalin and gabapentin is more limited than the placebo-controlled evidence for each drug individually.

A 2025 systematic review and meta-analysis of 14 comparative studies (3,346 adults) found that pregabalin produced modestly better pain scores than gabapentin, with a standardized mean difference of -0.47 on visual analog scale measures. The review also reported lower opioid use and better patient-reported outcomes with pregabalin. However, many of the included studies were observational rather than randomized, which limits the strength of this conclusion.

When each drug is tested individually against placebo, the efficacy gap narrows:

• Gabapentin: A Cochrane review found that at doses of 1,200 mg/day or higher, about 38% of adults with diabetic neuropathy achieved substantial relief compared to 23% with placebo, yielding a number needed to treat (NNT) of approximately 6.6.
• Pregabalin: A meta-analysis of randomized controlled trials reported similar efficacy estimates, with NNTs of 8 and 10 for the 30% and 50% pain-reduction thresholds, respectively.

Both the AAN's 2022 painful diabetic polyneuropathy guideline and the IASP NeuPSIG's 2025 update recommend gabapentinoids first-line for neuropathic pain, alongside tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs). Neither guideline ranks pregabalin above gabapentin or vice versa.

What this means practically: The efficacy difference between these two medications is small. The choice often depends more on the specific pain condition, side-effect tolerance, cost, and insurance coverage than on a clear winner in pain relief.

Side Effects and Safety

Both medications share a similar side-effect profile, which is expected given their shared mechanism.

Common side effects for both include:

• Dizziness
• Drowsiness (somnolence)
• Weight gain
• Peripheral edema (swelling in the hands and feet)
• Fatigue
• Blurred vision

A pooled analysis of randomized trials found that pregabalin increased adverse event risk compared to placebo, including dizziness, somnolence, weight gain, peripheral edema, and visual disturbances. A Cochrane epilepsy review comparing the two directly reported similar adverse event rates between pregabalin and gabapentin, though the included trials were short.

Scheduling difference: Pregabalin is a Schedule V controlled substance under federal law, meaning the DEA considers it to carry a low but real risk of dependence. Gabapentin is not federally scheduled, though several states (including Kentucky, Tennessee, Virginia, and West Virginia) have classified it as Schedule V at the state level.

Both medications carry FDA warnings about suicidal thoughts and behaviors, respiratory depression (especially when combined with opioids or other central nervous system depressants), and the risk of withdrawal symptoms if stopped abruptly. Tapering under medical supervision is recommended for both.

Cost and Insurance Coverage

Cost has historically been one of the biggest practical differences between these two medications, though that gap has narrowed since generic pregabalin became available.

• Generic gabapentin is widely available and typically costs \$10 to \$30 per month with insurance or a pharmacy discount.
• Generic pregabalin now costs roughly \$14 to \$40 per month with a discount.
• Brand-name Lyrica still runs \$600 or more per month without insurance.

Most insurance formularies place gabapentin in a lower cost tier than pregabalin, which can mean lower copays. Some plans require trying gabapentin first (step therapy) before covering pregabalin.

For patients comparing out-of-pocket costs, the difference between generic formulations is now modest. The brand-name premium for Lyrica remains substantial.

When Medication Alone Is Not Enough

Gabapentinoids help many people with nerve pain, but they do not work for everyone. In clinical trials, roughly 60% to 70% of participants did not achieve 50% pain relief from gabapentin alone. Even among those who respond, residual pain, functional limitations, and quality-of-life impacts often persist.

This is consistent with how neuropathic pain develops over time. Nerve pain involves not only peripheral nerve damage but also central nervous system changes that amplify pain signals. The brain and spinal cord can become more sensitive to pain input, a process researchers call central sensitization. When this happens, targeting only peripheral nerve signals with medication addresses part of the problem but not the full picture.

This is why major guidelines, including the AAN and IASP, recommend multimodal treatment rather than medication alone, combining pharmacotherapy with physical, psychological, and self-management approaches.

Non-Drug Approaches With Evidence for Nerve Pain

When medication partially helps but does not fully resolve symptoms, non-drug approaches can fill the gap. These are not replacements for medical care but work alongside it.

Behavioral and Mind-Body Approaches

Cognitive behavioral therapy (CBT) has the most published evidence among behavioral interventions for neuropathic pain. A randomized trial in adults with diabetic peripheral neuropathy found that CBT reduced pain interference and improved mental health functioning at 36-week follow-up compared to diabetes education alone.

A Cochrane review of 59 randomized trials found that CBT reduces pain and disability, as well as distress, in adults with chronic pain, with effects maintained at follow-up. The effects were small to moderate, but they address dimensions of the pain experience that medication does not typically reach, including catastrophizing, fear avoidance, and mood.

Other evidence-based behavioral approaches include:

• Acceptance and commitment therapy (ACT): Teaches psychological flexibility and value-based activity despite ongoing pain
• Mindfulness-based stress reduction (MBSR): Structured meditation training with evidence for chronic pain severity and function
• Pain neuroscience education: Helps patients understand how the nervous system generates and maintains pain, reducing threat perception and fear avoidance

These approaches work on the central nervous system's role in maintaining pain. When the brain interprets nerve signals as more threatening than they are, behavioral interventions can help recalibrate that response.

Physical and Movement-Based Approaches

Physical activity and structured exercise have evidence for several neuropathic pain conditions:

• In chemotherapy-induced peripheral neuropathy, a 2024 meta-analysis found that exercise improved symptoms and balance
• In spinal cord injury-related neuropathic pain, a 2023 systematic review found that voluntary, continuous exercise reduced pain, especially when started in the subacute phase
• Physical therapy focused on graded exposure and desensitization can help people with nerve pain gradually increase activity without triggering pain flares

The key is starting gradually and working with a clinician or therapist who understands neuropathic pain. Overly aggressive exercise can temporarily worsen symptoms in some individuals.

Other Approaches

• TENS (transcutaneous electrical nerve stimulation): Modest evidence for peripheral neuropathic pain; portable and low-risk
• Acupuncture: Some evidence for chemotherapy-induced neuropathy; less consistent evidence for other neuropathic conditions

How Lin Health Helps With Nerve Pain

Chronic nerve pain often involves more than damaged nerves. Over time, the brain and spinal cord can amplify pain signals even after the original cause stabilizes, a pattern researchers describe as nociplastic pain. This is where behavioral and mind-body approaches can have the most impact, by addressing the nervous system's learned pain response rather than only the peripheral nerve signals.

Lin Health's program is built on this principle. Using evidence-based modalities including CBT, ACT, and somatic tracking, the program helps people with chronic pain retrain their pain response. Each participant works one-on-one with a trained recovery coach through weekly live sessions, between-session chat support, and a structured app with learning and practice materials.

How it differs from self-guided programs or general therapy:

• Specialized in chronic pain conditions, not general mental health
• Coach-led and structured, with protocols designed by pain science experts
• Covered by most major insurance plans in Colorado, Texas, Florida, California, and New York, so most participants pay nothing out of pocket
• Short wait times, often with a same-day callback after signup

You can read how others with chronic pain have experienced the program at Lin Health patient stories.

If nerve pain medications have helped partially but symptoms still limit your daily life, a behavioral approach may be worth exploring alongside your current treatment.

See if Lin Health may help with your nerve pain

Most patients are fully covered by insurance. Wait times are short.

FAQ

What is the main difference between Lyrica and gabapentin?

Both are gabapentinoids that target calcium channels in the nervous system. The main practical differences are FDA approvals (pregabalin covers more pain conditions), cost (gabapentin is usually cheaper), and scheduling (pregabalin is a Schedule V controlled substance; gabapentin is not federally scheduled). Efficacy is similar for neuropathic pain.

‍Is Lyrica stronger than gabapentin?

A 2025 meta-analysis found pregabalin produced modestly better short-term pain scores than gabapentin. However, when each drug is compared to placebo individually, the numbers needed to treat are similar. "Stronger" depends on the individual, and clinicians may try both before finding what works.

Can I switch from gabapentin to Lyrica?

Yes, with your prescriber's guidance. The transition typically involves gradually reducing gabapentin while introducing pregabalin. Your clinician will calculate the equivalent dose. Do not stop gabapentin abruptly, as withdrawal symptoms can occur with both medications.

What non-drug options help with nerve pain?

Approaches with published evidence include CBT, physical therapy with graded exposure, structured exercise, and pain neuroscience education. These address the central nervous system's role in maintaining pain and are recommended alongside medication in major treatment guidelines.

Does insurance cover non-drug nerve pain treatment?

Coverage varies by plan. Programs like Lin Health are covered by most major insurance plans in select states, with many participants paying nothing out of pocket. Physical therapy and some forms of CBT are also commonly covered. Check with your insurer for specifics.

Are gabapentinoids safe to take long-term?

Both medications have been used long-term in clinical practice. Common concerns include weight gain, cognitive effects, and the potential for dependence, particularly with pregabalin. Regular check-ins with a prescriber help monitor whether the benefits continue to outweigh side effects.
This article is for informational purposes only and is not medical advice. It does not replace a conversation with a qualified healthcare provider. Talk with your clinician before making changes to any pain treatment plan.

Last reviewed: November 2026.